Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

More information: Swastika Sanyal et al, A system for inducible mitochondria-specific protein degradation in vivo, Nature Communications (2024). DOI: 10.1038/s41467-024-45819-6 Provided by ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

DNA-nanoparticle motors are exactly as they sound: tiny artificial motors that use the structures of DNA and RNA to propel ...

A new approach now in clinical trials called targeted protein degradation works a different way. Instead of inhibiting the troublemakers, these new therapies trick the cell’s natural garbage ...

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

Frizzled (FZD) proteins are the principal receptors of the Wnt signaling pathway. However, whether Wnt ligands induce FZD endocytosis and degradation remains elusive. The transmembrane E3 ubiquitin ...